We have identified two individuals of Greek Cypriot origin with thalassemia intermedia. Molecular analysis has shown that each individual is a compound heterozygote for a previously described p thalassemia allele and a novel mutation, C -+ G in position +33, in the 5' untranslated region of the p globin gene. In both families the p +33 allele is associated with the same p haplotype (-++-+++) suggesting that it is likely to be of a single origin. P-cDNAs from normal and mutant p alleles were isolated from peripheral blood reticulocytes using the technique of reverse transcription-polymerase chain reaction. Because the p +33 (C --t G) mutation creates a cutting site for the restriction enzyme NlalV, we could demonstrate by differential restriction analysis that the p gene with +33 mutation showed 25% to 35% residual activity compared with normal. The additive effect HE P-THALASSEMIAS are a group of inherited anemias characterized by a reduced production of /?-globin chain.' The vast majority are caused by point mutations, of which more than 130 have been characterized.'.? This catalogue of defects includes mutations that affect almost every known stage of gene expression and has been a model for other single gene disorders. Recently, a class of mutations in the S' untranslated region (S'UTR) of the /? globin gene has been described; this group includes two single base substitutions at positions +20 (C -+ G)4 and +22 (G + A)" and two minor deletions at positions + 10 (-T)6 and +40 to +43 (-AAAC),7 downstream of the cap site. Although these mutations in the S'UTR were associated with mild /? thalassemia, no formal demonstration that there is reduced mRNA output from the affected gene has been provided. We describe here a novel mutation (C + G) in the +33 position of the /? gene in two unrelated Greek Cypriot families and demonstrate that the mutation results in a moderate reduction in mRNA transcript derived from the mutant gene when compared with normal. Investigation of these two families have shown heterozygotes for the 0 +33 mutation alone, heterozygotes for the /? +33 mutation who have also coinherited different a thalassemia variants, compound heterozy- gotes for the /? +33 mutation, and 0 thalassemia alleles of different severity, both with and without coinheritance of a thalassemia.
gotes for the /? +33 mutation, and 0 thalassemia alleles of different severity, both with and without coinheritance of a thalassemia.
Using reverse transcription-polymerase chain reaction (RT-PCR) to isolate P-cDNAs from peripheral blood reticulocytes and restriction enzyme analysis, we could estimate the P-cDNAs derived from the normal /? and different /? thalassemia alleles from heterozygous or compound heterozygous individuals. The reduction in mRNA transcript produced by the /? thalassemia alleles was estimated and found to be in agreement with the spectrum of phenotypes as assessed by clinical status, hemoglobin (Hb), red blood cell indices, and globin chain biosynthesis ratios.
The interaction of the /? +33 C-G mutation with other /?
and a thalassemia variants has produced a complete spectrum of clinical phenotypes among the different individuals in these families and provides compelling evidence that globin chain imbalance is a major factor in determining the severity of disease in /? thalassemia. This novel mutation in the S'UTR emphasizes an important functional role of this region in the regulation of globin gene expression.
MATERIALS AND METHODS
Patients and hematology. Two kindreds, both of Greek Cypriot origin and unrelated, were studied. Blood samples were collected in EDTA as anticoagulant, and full blood profiles were obtained using an automated cell counter. Fresh blood was collected in heparin and kept on ice for globin chain biosynthesis studies. The percentage of Hb Az was measured by elution and spectrophotometry after cellulose acetate electrophoresis at pH 8.9 and Hb F by alkaline denaturation. Blood smears were stained for Hb H inclusions with brilliant cresyl blue. In vitro globin chain biosynthesis ratios were derived after incubation of peripheral reticulocytes with 'H-leucine and separation of the labelled globins on carboxymethyl-cellulose columns.x DNA analysis. DNA was extracted from peripheral blood leukocytes and analyzed by restriction enzyme digestion and Southern blotting.' Seven restriction fragment length polymorphisms (RFLPs) in the p globin gene cluster-HindII-c. HindIII-"y, HindIKAy, HindII-\kp, HindII-3'Qp, AvalI-P, and BamHI-P-were studied and 0 haplotypes derived.'" BamHI and BglII-digested DNA was hybridized with a and 5 globin gene probes, respectively. to determine the number of a globin genes.
The 0. 6 and a 2 globin genes were enzymatically amplified using the polymerase chain reaction (PCR): DNA sequences o f the oligonucleotide primers and thermal cycling conditions for specific nmplification of these genes have been described.""' In the PCR. one of the amplification primers was S'-biotinylated" to allow preparation of single-stranded (ss) template using magnetic beads (Dynabcads "280 Streptavidin) and a magnetic particle concentrator (MPC-E Dynal. Wirral, UK). The ss-template was then sequenced by the dideoxy chain termination method using the sequencing primers as described. A 464-bp segment at the S' end of the globin gene including the S'UTR was enzymatically amplified using primers API and AP2 and subjected to NlnlV-restriction analysis (see Fig I) . RNA onn/ysi.s. Fresh blood was collected in EDTA and kept on ice for RNA extraction. Total RNA was extracted using a modification of the Chomczynski-Sacchi methodI5 with a 14 mollL solution of guanidine salts and urea (Chaosolv) as protein denaturant and ribonuclease inhibitor (Biotecx Laboratories Inc. Houston. TX). followed by extraction with chloroform and isopropanol precipitation.
One microgram of total RNA was reverse transcribed into cDNA using an oligo (dT),, primer and avian myeloblastosis viral (AMV) reverse transcriptase in a buffer containing ribonuclease inhibitor (RNAsin 20 units). I mmol/L each of dGTP. dATP, dTTP, and dCTP, S mmol/L MgCI?, 10 mmol/L Tris-HCI pH 8.8. SO mmollL KCI, and 0.1% Triton X-100 in a 20-pL volume reaction. All reagents except dNTPs were supplied by Promega. Southampton. UK.
The reaction was performed at 42°C for IS minutes, followed by inactivation of the reverse transcriptase at 99°C for S minutes and cooling on ice. PCR amplification of a S' fragment of p cDNA containing the novel mutation was performed in a 100-pL reaction volume containing 0.2 mmollL each of dNTP's. SO mmollL KCI, I O mmol/L Tris-HCI pH 8.3, 2.5 mmol/L MgCI?, and 2.5 units Taq DNA polymerase using the primers AP3 and AP4 yielding a fragment of 276 bp (see Fig 2) . After an initial denaturation of 4 minutes at 94°C. 35 cycles of denaturation at 94°C for I minute. annealing at 56°C for 1 minute, and extension at 72°C for 30 seconds were applied. the last extension reaction was prolonged for S minutes. An aliquot of the PCR products was examined in a I .2% agarose gel. Hphl (GGJGA(N),) for the S-hp deletion affecting the S' splice junction o f lVSl of the a 2 globin gene. For confirmation of these mutations. aliquots of 0-cDNA isolated by RT-PCR or specifically amplilied genomic DNA were digested with the different restriction enzymes and the digested products electrophoresed on either 1.2% agarose or 4% Metaphor gels (FMC Bioproducts. Rockland, ME) and visualized under ultraviolet light after staining in 0.S pg/mL ethidium bromide. Oli,qopro/w h~6ritli:crfiorl. The electrophoresed NktlV-digested 8-cDNA was transferred from 4% Metaphor gels to positivelycharged nylon membranes (Biodync B, P a l l Biodync. Portsmouth. UK) using 0.S mollL NaOH. 1.S mollL NaCl as transfer buffcr. Filters were hybridized with an oligonuclcotidc probe complementary t o a sequence common t o the normal and mutant 0-cDNA (see Fig 2) in a 7% polyethylene glycol 6.0()0 o r 8.000 (PEG)/lO% sodium dodecyl sulfhtc (SDS) buffer. The primer was labelled by 3' end tailing with "P-dCTP using calf thymus deoxynucleotidyl terminal transferase (Tdt: Boehringer Mannhcim. Germany).
Rttrlioctcfi~v PCR r r r~d sr~rfric/rrrtrlfiftrfio,l of P-cIlNA />.Y .scirrfillcrfiorl cowlf, RNA was reverse transcrihed into p-cDNA as descrihed earlier (RNA analysis). A shorter (IS6-hp) fragment of 0-cDNA encompassing the S' end of the 0 globin gene including the S'UTR was amplified using AP3 and APS. a primer spanning exons I and 2 and thus specilic for normally spliced P-mRNA (see Fig S) . Initially, 1 0 pmol of APS was S' end-lahelled with y"P-dCTP using T4 Polynucleotide Kinase (USB. Cleveland. OH). in a buffer containing Tris-HCI 0.05 mollL (pH 7.6) , MgCI? 10 mmollL. and 2-mercaptoethanol 120 mmollL in a SO-pL reaction volume. The reaction was incubated at 37°C for 10 minutes and terminated by heating at 65°C for S minutes. Five microliters of this reaction containing I pmol of radioactively-labeled APS was added to 9 pmol cold APS. PCR p-mRNA, is amplified by the PCR using primers AP3 (as in Fig 2) and AP5 I5'-AGA CCA CCA GCA GCC TGC CCA-3'). Because AP5 spans exons 1 and 2, it is specific for normally spliced p-mRNA and should not detect the aberrantly spliced p-mRNA produced by the plVSl-110 mutation. (B) The C + G mutation at position +33 creates a site for Nla 1V such that digestion of p-cDNA produces two fragments of For personal use only. on November 11, 2017. by guest www.bloodjournal.org From family L) and 11-1. 11-2. and 11-3 in family H, because the p +33 C + G mutation creates a site for NlnlV, and all the 0-cDNA in these individuals is derived from p +33 C-G allele.
RESULTS
Familv H. The proband (11-2) is a 25-year old man of Greek Cypriot ancestry. He was clinically well until the age of 23 years, when he presented with lethargy and symptoms of a respiratory infection. On examination he had hepatosplenomegaly with severe anemia (Hb 4 g/dL, MCV 62.0 fL, MCH 19.2 pg) and reticulocytosis of 5.5%. Blood film showed anisocytosis, poikilocytosis, hypochromic microcytosis, target cells, and basophilic stippling. Hb H inclusions were not detected. HbAz was 6% and HbF was 4.8%.
He was transfused initially, but remained symptomatically anemic in the ensuing months. Splenectomy was performed with clinical improvement and an increase in Hb to 10 g/dL. The proband's parents and two siblings were all clinically asymptomatic. Their relevant hematologic results are shown in Table I ; the proband's mother (1-2) and two siblings (11-1, 11-3) have blood profiles consistent with &thalassemia trait, while his father (1-1) has very mild hypochromia and microcytosis with a reduced level of HbA2. Globin chain biosynthesis ratios in the proband. his mother. and one sibling (11-3) were consistent with P-thalassemia, while a balanced ratio was found in the father ( Table l) .
The proband's &globin genes were enzymatically amplified by PCR and sequenced from position -710 5' to the Cap site to I28 bp downstream of the termination site including all 3 exons, the first intron, most of the second intron and the splice junctions. He was found to be a compound heterozygote for the common Mediterranean C + T mutation in codon 39 and a novel mutation, C + G, at position +33 3' to the transcription initiation Cap site (Fig 4) . In particular, he did not have the (+ATA; -T) rearrangement at position -530" ie, he was homozygous for the (TA)6 T8 repeat at position -530. He was also heterozygous for the T-C variant at position -550 (detected by Rsal)." Presence of the 39 C + T mutation in the heterozygous form in the proband, his mother, and two siblings were confirmed by Bfal restriction analysis.Ix The +33 C + G mutation creates a site for NlaIV; C T A G For t Quantitation of the relative ratios of the p-cDNAs produced from the different p alleles in the heterozygotes and compound heterozygotes for the fl +33 C-G mutation. Ratios were obtained by scintillation count as described in Materials and Methods.
presence of the mutation in the heterozygous form in the proband, his father, and two siblings were shown by NlaIV restriction analysis of enzymatically amplified P gene ( Fig   1 ) .
P-globin cDNAs were isolated by RT-PCR of mRNA. In all cases, a specific fragment of 276 bp was produced, and this was digested with NlaIV. The products were separated on Metaphor gels, visualized directly after ethidium bromide staining followed by transfer onto nylon filters and hybridized with a radio-labelled oligoprobe (Fig 2) . Both methods allow the semiquantitative assessment of mRNA accumulation from normal and mutant alleles from each individual. Given the balanced chain biosynthesis ratio of the father with the reduced HbA2 level and minimal hypochromic microcytosis, it was possible that the novel base change at position +33 did not represent a p globin gene mutation. However, there was an obvious reduction in p mRNA transcript from the mutant allele (approximately 30%) compared with the normal allele in the father, as shown by NlaIV digestion of P-cDNA (Fig 2) . Though semiquantitative, this comparison is valid, as the products of the normal and mutant alleles from the same individual are obtained from the same RT-PCR. Moreover, a survey of 20 normal individuals showed absence of this base change (results not shown).
However, the p globin gene mutations alone could not explain the clearly discordant clinical phenotypes in the proband and his siblings who all had identical p genotypes. The father was investigated further to elucidate the molecular basis for the balanced alp chain synthesis and low HbAz level. Sequence analysis of his 6 globin genes was normal (results not shown). Coinheritance of a thalassemia was suspected; BamHI-a and BglII-< specific fragments were normal, thus excluding any a gene deletion. The a 2 globin genes in 1-1 were specifically amplified; direct sequence analysis showed a 5-bp deletion affecting the IVSl donor site of one of the a 2 globin genes causing a frameshift, a common nondeletional a thalassemia variant in the Mediterranean region.19 HphI digestion of amplified a 2 globin gene sequences demonstrated the inheritance of this a thalassemia variant in 11-1 and 11-3, but not in the proband or his mother (results not shown).
The inheritance by the proband and his siblings of the same p gene mutations (one from each parent), but different P haplotypes, suggests a recombination event between the 6 and P globin genes; this has been confirmed by more detailed analysis of polymorphisms 5' to the P gene. The P and a mutations found, which fully explain the phenotypes of the family, are detailed in Table 2 and depicted in a family tree in Fig 5. Family L. The proband (I-l), who is of Greek Cypriot ancestry, presented at the age of 63 with a 30-year history of chronic leg ulcers. He was found to have splenomegaly and anemia (Hb 9.5 g/dL) with normal serum ferritin (181 pg/L). Other features of his blood profile included hypochromic microcytosis (MCV 60.6 fL, MCH 18.4 pg) and a reticulocytosis of 5%. Hb electrophoresis showed HbAz of 6.4% and HbF of 3.5%. He was transfused intermittently for 2 years with little improvement in the leg ulcers and since then had remained free of blood transfusions. Three generations of this family were investigated, with the pedigree and relevant hematological results shown in Fig 6 and Table 1 , respectively. Apart from the proband, all family members are clinically well. BamHI-a and BglII-< specific fragments showed a one a gene deletion (ea/-CY"') in the proband's wife (1-2) and one daughter (11-3). Globin chain biosynthesis ratios (Table 1) suggested @-thalassemia in the proband, probably inherited by both daughters (11-2 and 11-3).
The P globin genes of the proband were amplified and directly sequenced from 750 bp 5' to the Cap site to 77 bp 3' downstream of the termination site, covering all 3 exons, the first intron, part of the second intron, and the splice junctions. This showed compound heterozygosity for the Mediterranean PIVS1 position 1 G "+ A mutation and the novel P +33 C --t G mutation as found in family H. These mutations were confirmed respectively by BspMI and NlaIV digests of amplified DNA, which also showed that the P +33 C -+ G was inherited in five other subjects (11-2, 11-3, 111-2, 111-3, and 111-5) (see Fig 3) , while the IVSl position 1 G -+ A mutation was present in the proband alone ( Table  2) . 1-1 was also homozygous for the (TA)6T8 variant at position -53016 and heterozygous for the polymorphic RsaI site at position -550." DNA sequence analysis showed that 11-1 is heterozygous for the P IVSl position l10 G + A mutation, which is inherited by all his offspring (111-1, III-2, and 111-3).
Thus, with respect to the novel 0 +33 C "+ G mutation in this family, there are three heterozygotes (11-2, 11-3, and 111-5), of which one (11-3) has coinherited a single a gene deletion, one compound heterozygote for the 0 +33 C -G and a p" mutation (proband I-1) and two compound heterozygotes for the P +33 and a severe P' thalassemia mutation (111-2 and 111-3) . Their phenotypes as assessed by clinical status, hemoglobin, red blood cell indices, and globin chain biosynthesis ratios are fully explained by their genotypes ( Table 2) .
Semiquantitation of cDNA obtained from normal and mutant P alleles. In both families, a comparison was made between cDNA from normal and P thalassemia alleles generated in the same RT-PCR from individuals who are heterozygotes or compound heterozygotes for the P +33 C "-* G mutation using the technique as described. The results of this analysis are shown in Fig 3 and Table 2 . In compound heterozygotes for the P +33 and P codon 39 (11-1, 11-2, and   11-3, family H) or , B IVSI-1 (I-1, family L) mutations, both p" thalassemia alleles, P-cDNA is derived solely from the P +33 allele. Activity of NlaIV restriction could thus be monitored by a complete digestion of P-cDNA in these individuals. P-cDNA derived from the novel P +33 mutation in individuals heterozygous for this mutation (HI-l, LII-2, LII-3, and LIIIJ) appears to be reduced to 25% to 35% of normal. In compound heterozygotes for the P +33 and P IVSI-110 mutations, some P-cDNA is derived from the latter allele and has been estimated to be 12% to 18% of the P +33 allele and, by deduction, 3% to 6% of normal (individuals 111-2 and 111-3 in Table 2 , lanes 6 and 7 in Fig 3C) . The small amount of 0-cDNA appears to be responsible for the difference between clinically asymptomatic and symptomatic phenotypes in the compound heterozygotes.
DISCUSSION
We have identified two individuals with thalassemia intermedia, both characterized by moderate anemia, increased HbA2 levels and slightly increased levels of HbF (<5%), a The phenotype of this novel mutation in the 5'UTR thus appears to be milder than that associated with the A -+ G mutation at position -29 in the TATA box, the most common p thalassemia mutation in blacks,22 the T-C mutation in IVS-1 position 6 (a common Mediterranean mutation), or the other mutations in the p globin promoter region. Unlike the p +33 C -+ G mutation, heterozygotes for these mutations have hypochromic microcytic red blood cells and borderline to increased HbA, levels, while compound heterozygotes with the p IVSI-l10 G-A mutation have fairly severe anemia.23-2' It should be noted that slightly elevated levels of Hb F are seen in heterozygotes for the p +33 C -+ G allele (LII-2 and L111-5), as observed in other p thalassemia heterozygotes (Table 1 ). In contrast, individuals HI-1 and LII-3, who are also heterozygotes for the p +33 C -+ G allele but have coinherited an a thalassemia variant with a concomitant reduction in a globin production, have normal Hb F levels. This difference in Hb F levels is also observed in HII-2 (proband) and his siblings, HII-I and HII-3 ( Table   1 ).
The possibility that the novel mutation did not downregulate the p gene was considered, but is unlikely given the reduction in p globin mFWA transcript from the mutant allele and the absence of the mutation in 20 normal individuals. Functional analysis of the 4-bp deletion at positions +40 to +43 in the 5'UTR of the p globin gene using reporter genes in transient expression assays failed to show any significant effect of this mutation, but this may not reflect the in vivo situation.26 There are two highly conserved sequences in the region between the capping site and the initiator ATG codon of the various mammalian p-like globin genesz7; one, within positions +6 to + 13, and the other, the seven 3' most nucleotides, the last three corresponding to the initiator ATG. Although the mutation at position +33 does not occur within one of these conserved sequences, alignment of the 5' noncoding sequence of the mammalian p-like globin genes shows that the C is predominant at this site in eight of the 10 &like globin genes (Fig 8) .
The possible mechanisms whereby this novel mutation in the 5'UTR downregulates the p globin gene can be divided into those that affect transcription andor translation. The finding of a reduced amount of transcript from the mutant allele suggests that the anomaly affects the transcriptional process or mRNA stability. The steady state level of cytoplasmic mRNA depends on the balance between its rate of formation and degradation. There is no known evidence for a transcriptional regulatory region within the 5'UTR of the p globin gene; hence, the reduced level of p globin transcript is likely to be due to increased mRNA degradation. Indeed
For personal use only. on November 11, 2017. by guest www.bloodjournal.org From This report describes the characterization of the genetic lesions in two families with atypical P thalassemia. A complete spectrum of phenotypic severity was demonstrated, fully explained by the genotypic abnormalities found. It illustrates the importance of family studies in unravelling complex molecular genotypes and in explaining apparent mismatches of genotype and phenotype. Globin chain biosynthesis ratios are crucial as an objective means of determining phenotype, and thus in directing the search for less obvious genotypic abnormalities, as in the involvement of nondeletional a thalassemia in family H. The concept of P-thalassemia as a polygenic disease, in which factors external to the P globin gene (such as the coinheritance of a thalassemia), is well demonstrated in this study.
While the functional role of the S'UTR in the P globin gene is not yet clear, the novel mutation appears to downregulate gene expression by reducing the amount of mRNA transcript. Other mutations in this region that are associated with P thalassemia further underline the physiological role of this region. Additional in vitro studies of promoter or enhancer activities of this region using marker genes may help to delineate its role in P globin gene regulation.
